Pharmaceuticals

Kevzara Market 2026–2035 strengthening autoimmune disease treatment

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Kevzara Market Expected To Change Between 2026 And 2030?

Historical expansion was propelled by a significant prevalence of rheumatoid arthritis, the inherent limitations of conventional DMARDs, the clinical achievements of biologics, the expansion of specialist rheumatology care, and enhanced diagnosis rates.

Growth anticipated during the forecast period can be attributed to the rising burden of autoimmune diseases, broader application in additional inflammatory indications, increased acceptance of biologic treatments, improved access to specialty medical care, and innovations in cytokine targeting.

Major trends identified for the forecast period include the increasing adoption of IL-6 inhibitors, a surge in biologic treatments for rheumatoid arthritis, the expansion of targeted anti-inflammatory therapies, a preference for injectable biologic medications, and a focused effort on long-term disease control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20127&type=smp

What Drivers Are Expected To Influence The Kevzara Market During The Forecast Period?

The increasing prevalence of rheumatoid arthritis (RA) is projected to significantly drive the expansion of the Kevzara market in the future. Rheumatoid arthritis (RA) is a persistent autoimmune condition that predominantly affects the joints, causing inflammation, discomfort, swelling, and stiffness. The widespread occurrence of rheumatoid arthritis (RA) can be attributed to several elements, including genetic predispositions, environmental triggers, hormonal influences, and immune system dysfunction. Kevzara addresses RA symptoms by specifically inhibiting IL-6, a protein known to fuel inflammation. This action helps alleviate inflammation, enhance joint health, and improve the overall quality of life for individuals living with the disease. For instance, in February 2024, according to Arthritis Australia, an Australia-based government agency, the number of Australians with arthritis is expected to climb from 4.11 million in 2025 to 5.39 million by 2040. Over the same period, instances of osteoarthritis are anticipated to increase from 2.35 million to 3.11 million, while the count of people suffering from rheumatoid arthritis is predicted to reach 748,721 by 2040. Consequently, the rising prevalence of rheumatoid arthritis (RA) is stimulating the growth of the Kevzara market. The surge in healthcare expenditure is anticipated to propel the expansion of the Kevzara market moving forward. Healthcare expenditure denotes the total financial resources allocated for healthcare services and products within a specific country or region. Several factors contribute to increased healthcare spending, including an aging population, advancements in medical technology, rising healthcare costs, an emphasis on preventive care, and broader health insurance coverage. Kevzara, as a high-cost biologic treatment for rheumatoid arthritis and other inflammatory conditions, requires ongoing administration, leading to long-term treatment expenses. Its substantial price significantly contributes to overall healthcare expenditure for both patients and healthcare systems. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure saw an increase of 5.6% in nominal terms between 2022 and 2023, compared with a growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is fueling the growth of the Kevzara market.

How Is The Kevzara Market Structured Across Different Segments?

The kevzara market covered in this report is segmented –

1) By Formulation: Injectable Formulation, Autoinjectors

2) By Indication: Treatment Of Moderate To Severe Rheumatoid Arthritis, Treatment Of Giant Cell Arteritis, Other Potential Indications

3) By Patient Demographic: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Specialty Clinics, Outpatient Treatment Centers, Home Healthcare Providers

Which Trends Are Shaping The Future Of The Kevzara Market?

A primary direction in the Kevzara market involves creating sophisticated products, specifically interleukin-6 (IL-6) receptor blocker medications, to broaden their use in treating various inflammatory conditions. These IL-6 receptor blocker medicines function as biological drugs, designed to target and inhibit IL-6, a protein known to fuel inflammatory responses, thereby aiding in the reduction of inflammation and the management of ailments like rheumatoid arthritis. As an illustration, during February 2023, Regeneron Pharmaceuticals Inc., a US biotechnology firm, alongside Sanofi, a French healthcare enterprise, jointly declared that Kevzara (sarilumab) had received approval from the U.S. Food and Drug Administration (FDA) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disorder affecting adults who have either shown insufficient response to corticosteroids or are unable to decrease their corticosteroid dosage. Kevzara operates by blocking the IL-6 receptor, contributing to a decrease in both inflammation and the intensity of the disease. Administered through subcutaneous injection, this medication presents an alternative option to prolonged reliance on steroids. Furthermore, the treatment has proven notably effective in helping PMR patients achieve lasting remission and lessening their need for corticosteroids.

Which Major Players Dominate The Kevzara Market?

Major companies operating in the kevzara market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Read the full kevzara market report here:

https://www.thebusinessresearchcompany.com/report/kevzara-global-market-report

Which Region Is Forecast To Lead The Kevzara Market In Terms Of Market Size?

North America was the largest region in the kevzara market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kevzara market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kevzara Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20127&type=smp

Browse Through More Reports Similar to the Global Kevzara Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

K Beauty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/k-beauty-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795